What it said it expected, against what it reported
2 targets with a reported result
Above the range
1
above the last range given
Within the range
0
of 2 range targets
Below the range
1
below the last range given
The numbers ELV said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from
| Target | What the company said | Reported | Result |
|---|---|---|---|
| Operating cash flow Fiscal 2026 |
Given at least $5.50B release 2026-04-22
Raised at least $6.00B release 2026-07-15
Raised at least $6.50B release 2026-10-21
|
– | Not reported yet |
The company's wordsRESULTS; RAISES FULL-YEAR GUIDANCE … Reaffirm FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter release 2026-04-22 FY 2026 operating cash flow guidance raised to at least $6.0 billion release 2026-07-15 FY 2026 operating cash flow guidance raised to at least $6.5 billion release 2026-10-21 | |||
| Diluted EPS (company-defined) Fiscal 2026 |
Given at least $27.00 release 2026-07-15
|
– | No standard number |
The company's wordsWe are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider connectivity, operating efficiency, and Carelon’s value-based solutions. release 2026-07-15 | |||
| Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31) |
Given $30.00 release 2025-07-17
|
– | No standard number |
The company's wordsRevising FY 2025 adjusted diluted EPS guidance to approximately $30.00 release 2025-07-17 | |||
| Diluted EPS Fiscal 2025 (ended 2025-12-31) |
Given $24.10 release 2025-07-17
|
$25.21 10-K filed 2026-02-06 |
Above the range |
The company's wordsGiven the ongoing and industry-wide impact of elevated cost trends in ACA and Medicaid, Elevance Health now expects 2025 GAAP net income per diluted share to be approximately $24.10 and adjusted net income per diluted share to be approximately $30.00. release 2025-07-17 | |||
| Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31) |
Given at least $34.29 release 2024-01-24
Lowered at least $34.05 release 2024-04-18
Raised at least $37.20 release 2024-07-17
|
– | No standard number |
The company's wordsSETS FULL YEAR 2024 OUTLOOK … Projected FY 2024 GAAP diluted EPS and adjusted diluted EPS2 of greater than $34.29 and $37.10 per share, respectively release 2024-01-24 FY 2024 diluted EPS and adjusted diluted EPS guidance raised to greater than $34.05 and $37.20, respectively release 2024-04-18 Elevance Health expects GAAP net income per diluted share to be at least $34.05 in 2024, and adjusted diluted net income per share to be at least $37.20. release 2024-07-17 | |||
| Diluted EPS Fiscal 2024 (ended 2024-12-31) |
Given $26.50 release 2024-10-17
|
$25.68 10-K filed 2025-02-20 |
Below the range |
The company's wordsGiven third quarter results and the timing mismatch between Medicaid rates and acuity, Elevance Health now expects 2024 GAAP net income per diluted share to be approximately $26.50 and adjusted net income per diluted share to be approximately $33.00. release 2024-10-17 | |||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-01-24), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.